Expression of purinergic receptors in non-melanoma skin cancers and their functional roles in A431 cells.

We investigated the use of purinergic receptors as a new treatment modality for nonmelanoma skin cancers. Purinergic receptors, which bind adenosine 5'-tri-phosphate, are expressed on human cutaneous keratinocytes. Previous work in rat and human epidermis suggested functional roles for purinergic receptors in the regulation of proliferation, differentiation, and apoptosis. Immunohistochemical analysis of frozen sections in human basal cell carcinomas and squamous cell carcinomas for P2X5, P2X7, P2Y1, P2Y2, and P2Y4 receptors was performed, accompanied by detailed analysis of archive material of tumor subtypes in paraffin sections. Functional studies were performed using a human cutaneous squamous cell carcinoma cell line (A431), where purinergic receptor subtype agonists were applied to cells and changes in cell number were quantified via a colorimetric assay. Immunostaining in paraffin sections was essentially the same as that in frozen sections, although more detail of the subcellular composition was visible. P2X5 and P2Y2 receptors were heavily expressed in basal cell carcinomas and squamous cell carcinomas. P2X7 receptors were expressed in the necrotic center of nodular basal cell carcinomas and in apoptotic cells in superficial multifocal and infiltrative basal cell carcinomas, and squamous cell carcinomas. P2Y1 receptors were only expressed in the stroma surrounding tumors. P2Y4 receptors were found in basal cell carcinomas but not in squamous cell carcinomas. P2X5 receptors appear to be associated with differentiation. The P2X7 receptor agonist benzoylbenzoyl-adenosine 5'-triphosphate and high concentrations of adenosine 5'-triphosphate (1000-5000 microM) caused a significant reduction in A431 cell number (p<0.001), whereas the P2Y2 receptor agonist uridine 5'-triphosphate caused a significant amount of proliferation (p<0.001). We have demonstrated that non-melanoma skin cancers express functional purinergic receptors and that P2X7 receptor agonists significantly reduce cell numbers in vitro.

[1]  Ferguson.  Urothelial function , 1999, BJU international.

[2]  W. Webb,et al.  Studies on the increase in cytosolic free calcium induced by epidermal growth factor, serum, and nucleotides in individual A431 cells , 1988, Journal of cellular physiology.

[3]  G. Burnstock.  A basis for distinguishing two types of purinergic receptor , 1978 .

[4]  G. Burnstock,et al.  Expression of P2 receptors in bone and cultured bone cells. , 2000, Bone.

[5]  J. Boeynaems,et al.  Effects of extracellular nucleotides and nucleosides on prostate carcinoma cells , 2001, British journal of pharmacology.

[6]  S. Strom,et al.  Epidemiology of nonmelanoma skin cancer. , 1997, Clinics in plastic surgery.

[7]  R. North.  Molecular physiology of P2X receptors. , 2002, Physiological reviews.

[8]  M. Berridge.  Inositol lipids and DNA replication. , 1987, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[9]  R. Evans,et al.  Agonist‐stimulated internalisation of the ligand‐gated ion channel P2X1 in rat vas deferens , 2001, FEBS letters.

[10]  G. Burnstock,et al.  ATP regulates the differentiation of mammalian skeletal muscle by activation of a P2X5 receptor on satellite cells , 2002, The Journal of cell biology.

[11]  J. Estrela,et al.  Inhibition of cancer growth and selective glutathione depletion in Ehrlich tumour cells in vivo by extracellular ATP. , 1994, The Biochemical journal.

[12]  I. Friedberg,et al.  Growth inhibition of breast cancer cells induced by exogenous ATP , 1993, Journal of cellular physiology.

[13]  F. Di Virgilio,et al.  Mouse microglial cells express a plasma membrane pore gated by extracellular ATP. , 1996, Journal of immunology.

[14]  S. Batra,et al.  Calcium mobilization and cell proliferation activated by extracellular ATP in human ovarian tumour cells. , 1993, Cell calcium.

[15]  E. Mooney,et al.  Apoptotic and mitotic indices in malignant melanoma and basal cell carcinoma. , 1995, Journal of clinical pathology.

[16]  J. D. Young,et al.  Extracellular ATP as a trigger for apoptosis or programmed cell death , 1991, The Journal of cell biology.

[17]  G. Argenziano,et al.  Prognostic value of apoptotic index in cutaneous basal cell carcinomas of head and neck. , 1999, Oral oncology.

[18]  M A Weinstock,et al.  Nonmelanoma skin cancer in the United States: incidence. , 1994, Journal of the American Academy of Dermatology.

[19]  I. Llewellyn-Smith,et al.  The tungstate-stabilized tetramethylbenzidine reaction for light and electron microscopic immunocytochemistry and for revealing biocytin-filled neurons , 1993, Journal of Neuroscience Methods.

[20]  R. Christopherson,et al.  Extracellular ATP-dependent suppression of proliferation and induction of differentiation of human HL-60 leukemia cells by distinct mechanisms. , 2000, Biochemical pharmacology.

[21]  R. Hipskind,et al.  Extracellular ATP activates multiple signalling pathways and potentiates growth factor-induced c-fos gene expression in MCF-7 breast cancer cells. , 2000, Carcinogenesis.

[22]  Stanley J. Miller,et al.  Biology of basal cell carcinoma (Part II). , 1991, Journal of the American Academy of Dermatology.

[23]  R. Gillies,et al.  Determination of cell number in monolayer cultures. , 1986, Analytical biochemistry.

[24]  J. Kanellopoulos,et al.  P2Z/P2X7receptor-dependent apoptosis of dendritic cells. , 1999, American journal of physiology. Cell physiology.

[25]  B. Sperlágh,et al.  Neuronal synthesis, storage and release of ATP , 1996 .

[26]  A. Wetter,et al.  Molecular pharmacology of P2Y-receptors , 2000, Naunyn-Schmiedeberg's Archives of Pharmacology.

[27]  T. Egan,et al.  Identification of a Domain Involved in ATP-gated Ionotropic Receptor Subunit Assembly* , 1999, The Journal of Biological Chemistry.

[28]  L. Heppel,et al.  Extracellular ATP is a mitogen for 3T3, 3T6, and A431 cells and acts synergistically with other growth factors. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[29]  K. Yoshikawa,et al.  Expression of proliferating cell nuclear antigen/cyclin in human keratinocytes. , 1989, The Journal of investigative dermatology.

[30]  G. Bilbe,et al.  Regulation of epidermal homeostasis through P2Y2 receptors , 1999, British journal of pharmacology.

[31]  G. Burnstock,et al.  Increased release of ATP from endothelial cells during acute inflammation , 1998, Inflammation Research.

[32]  G. Burnstock,et al.  Sequential expression of three receptor subtypes for extracellular ATP in developing rat skeletal muscle , 2001, Developmental dynamics : an official publication of the American Association of Anatomists.

[33]  L. Bolis,et al.  Cell membrane receptors for drugs and hormones : a multidisciplinary approach , 1978 .

[34]  D. Ferrari,et al.  P2Z purinoreceptor ligation induces activation of caspases with distinct roles in apoptotic and necrotic alterations of cell death , 1999, FEBS letters.

[35]  G. Burnstock,et al.  Localisation of P2X5 and P2X7 receptors by immunohistochemistry in rat stratified squamous epithelia , 1999, Cell and Tissue Research.

[36]  Stanley J. Miller,et al.  Biology of basal cell carcinoma (Part I). , 1991, Journal of the American Academy of Dermatology.

[37]  M. Raff,et al.  Caspase activation in the terminal differentiation of human epidermal keratinocytes , 1999, Current Biology.

[38]  K. Malinovszky,et al.  Changing trends in non‐melanoma skin cancer in South Wales, 1988–98 , 2000, The British journal of dermatology.

[39]  G. Burnstock,et al.  Purinergic signalling: pathophysiological roles. , 1998, Japanese journal of pharmacology.

[40]  M. Bennett,et al.  The Distribution of P2X Receptor Clusters on Individual Neurons in Sympathetic Ganglia and Their Redistribution on Agonist Activation* , 2000, The Journal of Biological Chemistry.

[41]  G. Burnstock.  Purinergic Signaling and Vascular Cell Proliferation and Death , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[42]  H. O. Kim,et al.  Purinoceptor-mediated calcium mobilization and proliferation in HaCaT keratinocytes. , 2001, Journal of dermatological science.

[43]  M. Bennett,et al.  P2X1 receptor membrane redistribution and down-regulation visualized by using receptor-coupled green fluorescent protein chimeras , 2000, Neuropharmacology.

[44]  G. Burnstock.  Purinergic signalling in development , 2001 .

[45]  Y. Bang,et al.  P2-purinergic receptor agonists inhibit the growth of androgen-independent prostate carcinoma cells. , 1992, The Journal of clinical investigation.

[46]  M. Parmentier,et al.  Identification of a Novel Human ADP Receptor Coupled to Gi * , 2001, The Journal of Biological Chemistry.

[47]  E. Kawashima,et al.  The Cytolytic P2Z Receptor for Extracellular ATP Identified as a P2X Receptor (P2X7) , 1996, Science.

[48]  B S Khakh,et al.  International union of pharmacology. XXIV. Current status of the nomenclature and properties of P2X receptors and their subunits. , 2001, Pharmacological reviews.

[49]  B. Khakh,et al.  Activation-dependent changes in receptor distribution and dendritic morphology in hippocampal neurons expressing P2X2-green fluorescent protein receptors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[50]  S. Ben‐Sasson,et al.  Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation , 1992, The Journal of cell biology.

[51]  W. Kueng,et al.  Quantification of cells cultured on 96-well plates. , 1989, Analytical biochemistry.

[52]  G. Burnstock,et al.  Purinergic receptors are part of a functional signaling system for proliferation and differentiation of human epidermal keratinocytes. , 2003, The Journal of investigative dermatology.

[53]  S. Stojilkovic,et al.  Expression and responsiveness of P2Y2 receptors in human endometrial cancer cell lines. , 1999, The Journal of clinical endocrinology and metabolism.

[54]  S. Stojilkovic,et al.  Characterization of calcium-mobilizing, purinergic P2Y(2) receptors in human ovarian cancer cells. , 2000, Molecular human reproduction.

[55]  G. Wilson,et al.  Cellular proliferation characteristics do not account for the behaviour of horrifying basal cell carcinoma. A comparison of the growth fraction of horrifying and non horrifying tumours. , 1998, British journal of plastic surgery.

[56]  M. Gavish,et al.  Expression of functional P2-purinergic receptors in primary cultures of human colorectal carcinoma cells. , 1998, Biochemical and biophysical research communications.

[57]  F. Di Virgilio,et al.  Extracellular ATP triggers IL-1 beta release by activating the purinergic P2Z receptor of human macrophages. , 1997, Journal of immunology.

[58]  G. Burnstock,et al.  Purinoceptors: are there families of P2X and P2Y purinoceptors? , 1994, Pharmacology & therapeutics.

[59]  C. Dixon,et al.  Extracellular nucleotides stimulate proliferation in MCF-7 breast cancer cells via P2-purinoceptors. , 1997, British Journal of Cancer.